Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2000

View Archived Issues

Atlantic submits IND for CT-3 to FDA; phase I trials to commence in France

Amarillo Biosciences reports phase III results for interferon alfa in Sjogren's syndrome

Celgene awarded patent for drug distribution system

Proof of concept demonstrated for PPL's transgenic BSSL

Clinical hold placed on South African study of Coviracil

Memantine improves cognition in vascular dementia patients

SangCya approved in Germany

Magainin discovers additional aminosterols with therapeutic potential

CV Therapeutics receives milestone from Biogen

Potential new diagnostic for AD presented by Axonyx

Periodontix's histatin mouthrinse reduces plaque and gingivitis

L-Arginine prevents chronic ciclosporin-induced renal dysfunction in heart transplant recipients

Canine studies demonstrate efficacy of NIP-142 in atrial flutter

Deleterious effects reported for ET antagonist immediately following MI in rat model

Japanese investigators explore uses for new chymase inhibitor SUN-C8257

NU-3108: profile of a novel nucleoside transport inhibitor

Small-molecule AICARFT inhibitors in the pipeline at Agouron

New benzodiazepinone derivatives under study at Aventis as inhibitors of bone resorption

Pfizer's new opioid receptor ligands claimed for use in painful, inflammatory and other disorders

Roche describes new ligands for the opioid-like receptor OFQ with a piperidine structure

Novel dihydrobenzopyrans exert both antiarrhythmic and antifibrillatory activities

Potent inhibition of human PDE4 reported for new Kyowa Hakko compound

Antitumor activity and pharmacokinetics of new taxoid TXD-258 discussed at ACS meeting

Aradigm announces gene therapy research collaboration with UCSF

New ocular antibiotic enters the pipeline at InSite Vision

Servier succeeds in improving antitumor activity of acronycine with S-23906-1

AVI-4126, a novel antisense compound; preclinical data presented recently support phase I/II trials

Keppra receives Swiss approval for treatment of epilepsy